Pubmed Biomarker P-value Description
34109467 HE4 p<0.001 Serum HE4 levels was significantly associated with older age
16980945 AIB1 High plasma GDF-15 was significantly associated with older age
36715558 HE4 p=0.02 Older age (odds ratio [OR] 0.96, 95% CI 0.93-0.99, p = 0.02), baseline serum HE4 (OR 0.97, 95% CI 0.96-0.99, p = 0.001) and endometrial cancer histology (OR 0.22, 95% CI 0.72-0.68, p = 0.009) were associated with a lower likelihood of progestin treatment response.
30134343 PD-L1 p=0.013 There was a significant difference between the staining scores of PD-L1 in tumor cells and age
30134343 PD-L2 p=0.043 a difference was found between the staining scores of PD-L2 in immune cells and age
29898448 ProGRP(Gastrin-releasing peptide) p=0.006 Age was positively correlated with ProGRP levels(r=0.322)
28965628 cyclin D1 p=0.0001 High score cyclin D1 immunohistochemical staining has been significantly linked with patient age
26763250 POLE exonuclease domain mutations (EDM) p<0.001 The median age of POLE mutated patients (58 years) was statistically different from patients with POLE wild-type tumours (66 years).
26763250 POLE exonuclease domain mutations (EDM) A logistic regression model with variable selection to show that the odds of having a POLE mutation were decreased with age (OR (odds ratio) 0.94 (95% CI 0.9-0.99) per year), BMI (OR 0.92 (95% CI 0.84-0.98) per unit increase) and advanced Stage (OR 0.04 (95% CI 0-0.39) relative to Stage I).
21616994 GDF-15 p<0.001 As the age of the patient decreased, the tumour was found to show less oestrogen receptor expression
17130035 oestrogen receptor p=0.003 AIB1 expression correlates with older age